retatrutide updates Phase III study demonstrates 30% weight loss Lilly Prepares for Retatrutide FDA

Call to learn more

Theoretically, increasing GLP-1 before a meal may decrease appetite and the amount eaten

Hazard Potential: Retatrutide may cause hypoglycemia or gastrointestinal distress in living subjects if misused

Understanding individual triggers and patterns helps inform personalised management strategies

Cardiovascular exercise (walking, jogging, cycling, swimming) also supports your health during GLP-1 treatment by improving cardiovascular fitness, supporting mental health, and contributing to caloric expenditure

These findings are from a controlled trial setting and may not reflect outcomes in broader or unsupervised populations